Back to Search
Start Over
Survival In Advanced Diffuse Large B-Cell Lymphoma In Pre- and Post-Rituximab Eras In The United States: A Population Based Study
- Source :
- Blood; November 2013, Vol. 122 Issue: 21 p1747-1747, 1p
- Publication Year :
- 2013
-
Abstract
- Rituximab was approved by FDA as first line agent for treatment of advanced diffuse large B-cell lymphoma (DLBCL) on February 2006. We conducted this population based study to determine if the results from clinical trials have translated into survival benefit in general population.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 122
- Issue :
- 21
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs57008490
- Full Text :
- https://doi.org/10.1182/blood.V122.21.1747.1747